Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
2 h) J, u5 _& L6 v9 ~& G2 {) K& u# H* p
8 w& r5 e% P) I) N( R4 n2 ~: N
Sub-category:
$ f h# Y" `4 U& a( x- Z. lMolecular Targets
- N3 G2 ^ G; k+ A- Z& U) z& E& a; z7 |& G9 j2 A
: S& S% @8 r' m8 N8 {) B! ]
Category:
/ d8 o$ q& ?( F. b) C3 _1 lTumor Biology 5 ^8 }2 }; m0 W+ n, t
+ ^$ X1 @2 x1 m& `6 @
+ ^) Y; E' o3 @) ]Meeting:) U) H- y. G; o) c5 J
2011 ASCO Annual Meeting
; z+ B0 B, X" F$ a( N* i- x* p1 |; v$ X r9 ^$ Y+ O; ]& r
! c! q" I0 A4 u8 ]$ p
Session Type and Session Title:4 b7 j! t) T |
Poster Discussion Session, Tumor Biology
$ m @& Y, b8 } }$ Z( J
/ d2 }3 T2 _3 C. g& ^$ U- M. A! c6 F
Abstract No:
2 \ s) Y7 p1 }$ H9 }10517 ! [( U7 k: d1 g6 i S$ v# [
( B1 I! Z. o. R1 @
. p7 K# l1 l7 _' r8 a& n' _Citation:
) G$ Y) Q4 s( C- C( T* }) UJ Clin Oncol 29: 2011 (suppl; abstr 10517)
8 Z% t# u1 K' e' w! z' t- ]
8 ?# w Y" C# v. n0 `, Q$ z) [8 K& i
Author(s):
, }$ n5 y5 ]. h, k7 r& jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 A6 h6 t: y+ e) z; G, \- }" d+ V& L8 t: T3 u$ l
) T/ ^2 @! L6 G' b$ M1 f, o
. y5 h4 E, g1 V) ~7 b5 y+ e
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
- c( j, J8 F0 j& m1 Y, h$ A% j. N1 Q+ t' b: N
Abstract Disclosures* t W3 |, _ c% m P4 c% n g8 `
+ x2 a) [) A7 o7 [, |Abstract:5 q& M; }; a% B& {
- [* @7 y% B( p4 k, l, `7 y2 L& f& [. q" @" f- O* Z8 a
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 @0 q9 @6 j7 F) |- a( p( ]6 d
$ w, M2 b7 r, q8 {# {# l
5 j/ j& _; Y! p- S" [ O+ H |